DBV Technologies S.A. (DBVT)Healthcare | Biotechnology | Châtillon, France | NasdaqCM
15.98 USD
-0.51
(-3.093%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 15.98 |
Hot Take ↕ | July 11, 2026, 4:25 a.m. EDT
The stock presents a classic biotech value trap where a massive analyst price target and recent price recovery mask deteriorating fundamentals. While the price has surged nearly 1,200% year-over-year, this is driven by a specific clinical milestone (VIASKIN filing) rather than sustainable business growth, evidenced by nine consecutive years of negative revenue growth prior to this spike and a trailing twelve-month loss of 78%. The balance sheet is fragile, with operating cash flow burning at -$150 million and negative free cash flow, while the company trades at a premium valuation relative to sales despite having no earnings. For the short term, the recent volatility and lack of a clear trend suggest a neutral stance, but the long-term outlook is severely compromised by the inability to generate consistent revenue or profits, making it a poor candidate for buy-and-hold strategies. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.150389 |
| AutoETS | 0.152103 |
| AutoARIMA | 0.314326 |
| AutoTheta | 0.318575 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 18.25 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.152 |
| Excess Kurtosis | -1.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.934 |
| Revenue per Share | 0.13 |
| Market Cap | 945,803,264 |
| Forward P/E | -32.44 |
| Beta | -0.21 |
| Website | https://www.dbv-technologies.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.613503 |
| Address1 | BAtiment IRO |
| Address2 | 107 Av. de la REpublique |
| All Time High | 101.14 |
| All Time Low | 0.441 |
| Ask | 16.12 |
| Ask Size | 1 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 234,280 |
| Average Daily Volume3 Month | 251,791 |
| Average Volume | 251,791 |
| Average Volume10Days | 234,280 |
| Beta | -0.212 |
| Bid | 15.91 |
| Bid Size | 2 |
| Book Value | 3.515 |
| City | Châtillon |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 15.98 |
| Current Ratio | 4.763 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 16.4791 |
| Day Low | 15.63 |
| Debt To Equity | 2.934 |
| Display Name | DBV |
| Earnings Call Timestamp End | 1,722,375,000 |
| Earnings Call Timestamp Start | 1,722,375,000 |
| Earnings Timestamp | 1,785,355,200 |
| Earnings Timestamp End | 1,785,355,200 |
| Earnings Timestamp Start | 1,785,355,200 |
| Ebitda | -165,162,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.375 |
| Enterprise To Revenue | 125.984 |
| Enterprise Value | 722,642,368 |
| Eps Current Year | -0.45525 |
| Eps Forward | -0.49264848 |
| Eps Trailing Twelve Months | -4.5 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 17.7995 |
| Fifty Day Average Change | -1.8195 |
| Fifty Day Average Change Percent | -0.10222197 |
| Fifty Two Week Change Percent | 61.350296 |
| Fifty Two Week High | 26.185 |
| Fifty Two Week High Change | -10.205 |
| Fifty Two Week High Change Percent | -0.38972694 |
| Fifty Two Week Low | 8.51 |
| Fifty Two Week Low Change | 7.4699993 |
| Fifty Two Week Low Change Percent | 0.87779075 |
| Fifty Two Week Range | 8.51 - 26.185 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,413,984,600,000 |
| Float Shares | 35,254,055 |
| Forward Eps | -0.49264848 |
| Forward P E | -32.43692 |
| Free Cashflow | -87,206,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 161 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 5,736,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.37248 |
| Implied Shares Outstanding | 59,186,686 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,717,718,400 |
| Last Split Factor | 1:2 |
| Long Business Summary | DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France. |
| Long Name | DBV Technologies S.A. |
| Market | us_market |
| Market Cap | 945,803,264 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_7406282 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -167,447,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 961,149,982 |
| Number Of Analyst Opinions | 6 |
| Open | 16.17 |
| Operating Cashflow | -150,580,992 |
| Operating Margins | -53.111107 |
| Payout Ratio | 0.0 |
| Phone | 33 1 55 42 78 78 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 15.98 |
| Post Market Time | 1,783,973,404 |
| Previous Close | 16.49 |
| Price Eps Current Year | -35.101593 |
| Price Hint | 2 |
| Price To Book | 4.5462303 |
| Price To Sales Trailing12 Months | 164.88899 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.716 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.83333 |
| Region | US |
| Regular Market Change | -0.51 |
| Regular Market Change Percent | -3.09278 |
| Regular Market Day High | 16.4791 |
| Regular Market Day Low | 15.63 |
| Regular Market Day Range | 15.63 - 16.4791 |
| Regular Market Open | 16.17 |
| Regular Market Previous Close | 16.49 |
| Regular Market Price | 15.98 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 129,514 |
| Return On Assets | -0.66355 |
| Return On Equity | -1.5888801 |
| Revenue Growth | 0.125 |
| Revenue Per Share | 0.13 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 59,186,686 |
| Shares Percent Shares Out | 0.022 |
| Shares Short | 1,299,136 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,666,927 |
| Short Name | DBV Technologies S.A. |
| Short Percent Of Float | 0.022 |
| Short Ratio | 4.18 |
| Source Interval | 15 |
| Symbol | DBVT |
| Target High Price | 54.89342 |
| Target Low Price | 5.81329 |
| Target Mean Price | 40.637943 |
| Target Median Price | 46.892735 |
| Total Cash | 229,200,000 |
| Total Cash Per Share | 3.873 |
| Total Debt | 6,100,000 |
| Total Revenue | 5,736,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.5 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 18.06964 |
| Two Hundred Day Average Change | -2.0896397 |
| Two Hundred Day Average Change Percent | -0.11564369 |
| Type Disp | Equity |
| Volume | 129,514 |
| Website | https://www.dbv-technologies.com |
| Zip | 92,320 |